Hamostaseologie 2022; 42(06): 409-419
DOI: 10.1055/a-1755-8676
Review Article

Assessment and Monitoring of Coagulation in Patients with COVID-19: A Review of Current Literature

Günalp Uzun
1   Center for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
,
Karina Althaus
1   Center for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
2   Medical Faculty of Tuebingen, Institute for Clinical and Experimental Transfusion Medicine, Tuebingen, Germany
,
Stefanie Hammer
1   Center for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
,
Tamam Bakchoul
1   Center for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany
2   Medical Faculty of Tuebingen, Institute for Clinical and Experimental Transfusion Medicine, Tuebingen, Germany
› Author Affiliations
Funding This work was supported by grants from the German Research Foundation and from the Herzstiftung to T.B. (BA5158/4 and TSG-Study).

Abstract

Coagulation abnormalities are common in patients with COVID-19 and associated with high morbidity and mortality. It became a daily challenge to navigate through these abnormal laboratory findings and deliver the best possible treatment to the patients. The unique character of COVID-19-induced coagulopathy necessitates not only a dynamic follow-up of the patients in terms of hemostatic findings but also the introduction of new diagnostic methods to determine the overall function of the coagulation system in real time. After the recognition of the high risk of thromboembolism in COVID-19, several professional societies published their recommendations regarding anticoagulation in patients with COVID-19. This review summarizes common hemostatic findings in COVID-19 patients and presents the societal recommendations regarding the use of coagulation laboratory findings in clinical decision-making. Although several studies have investigated coagulation parameters in patients with COVID-19, the methodological shortcomings of published studies as well as the differences in employed anticoagulation regimens that have changed over time, depending on national and international guidelines, limit the applicability of these findings in other clinical settings. Accordingly, evidence-based recommendations for diagnostics during acute COVID-19 infection are still lacking. Future studies should verify the role of coagulation parameters as well as viscoelastic methods in the management of patients with COVID-19.

Authors' Contributions

G.U., K.A., S.H., and T.B. searched the literature, reviewed the available articles, and wrote the manuscript. All authors read and approved the final manuscript.




Publication History

Received: 16 May 2021

Accepted: 28 January 2022

Article published online:
27 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with COVID-19. N Engl J Med 2020; 382 (26) 2534-2543
  • 2 Grasselli G, Greco M, Zanella A. et al; COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020; 180 (10) 1345-1355
  • 3 Helms J, Tacquard C, Severac F. et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46 (06) 1089-1098
  • 4 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
  • 5 Nahum J, Morichau-Beauchant T, Daviaud F. et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open 2020; 3 (05) e2010478
  • 6 Llitjos J-F, Leclerc M, Chochois C. et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; 18 (07) 1743-1746
  • 7 Wichmann D, Sperhake J-P, Lütgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; 173 (04) 268-277
  • 8 Nadkarni GN, Lala A, Bagiella E. et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76 (16) 1815-1826
  • 9 Thachil J, Juffermans NP, Ranucci M. et al. ISTH DIC subcommittee communication on anticoagulation in COVID-19. J Thromb Haemost 2020; 18 (09) 2138-2144
  • 10 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
  • 11 Kaptein FHJ, Stals MAM, Grootenboers M. et al; Dutch COVID & Thrombosis Coalition. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thromb Res 2021; 199: 143-148
  • 12 Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020; 7 (06) e438-e440
  • 13 Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020; 20 (06) 363-374
  • 14 Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383 (23) 2255-2273
  • 15 Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol 2021; 8 (07) e524-e533
  • 16 Bhattacharyya R, Iyer P, Phua GC, Lee JH. The interplay between coagulation and inflammation pathways in COVID-19-associated respiratory failure: a narrative review. Pulm Ther 2020; 6 (02) 215-231
  • 17 Hottz ED, Azevedo-Quintanilha IG, Palhinha L. et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood 2020; 136 (11) 1330-1341
  • 18 Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care 2020; 24 (01) 360
  • 19 Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation?. Intern Emerg Med 2021; 16 (02) 309-312
  • 20 Zhou X, Cheng Z, Luo L. et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb Res 2021; 201: 23-29
  • 21 Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res 2020; 69 (12) 1181-1189
  • 22 Suh YJ, Hong H, Ohana M. et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology 2021; 298 (02) E70-E80
  • 23 Jevnikar M, Sanchez O, Chocron R. et al. Prevalence of pulmonary embolism in patients with COVID 19 at the time of hospital admission. Eur Respir J 2021; 58 (02) 2101033
  • 24 Jin X, Duan Y, Bao T. et al. The values of coagulation function in COVID-19 patients. PLoS One 2020; 15 (10) e0241329
  • 25 Luo H-C, You C-Y, Lu S-W, Fu Y-Q. Characteristics of coagulation alteration in patients with COVID-19. Ann Hematol 2021; 100 (01) 45-52
  • 26 Reyes Gil M, Gonzalez-Lugo JD, Rahman S. et al. Correlation of coagulation parameters with clinical outcomes during the coronavirus-19 Surge in New York: observational cohort. Front Physiol 2021; 12: 618929
  • 27 Velasco-Rodríguez D, Alonso-Dominguez J-M, Vidal Laso R. et al. Development and validation of a predictive model of in-hospital mortality in COVID-19 patients. PLoS One 2021; 16 (03) e0247676
  • 28 Xiang G, Hao S, Fu C. et al. The effect of coagulation factors in 2019 novel coronavirus patients: a systematic review and meta-analysis. Medicine (Baltimore) 2021; 100 (07) e24537
  • 29 Zhang A, Leng Y, Zhang Y. et al. Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19. Int J Infect Dis 2020; 100: 441-448
  • 30 Hannawi S, Hannawi H, Naeem KB. et al. Clinical and laboratory profile of hospitalized symptomatic COVID-19 patients: case series study from the first COVID-19 center in the UAE. Front Cell Infect Microbiol 2021; 11: 632965
  • 31 Dujardin RWG, Hilderink BN, Haksteen WE. et al. Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients. Thromb Res 2020; 196: 308-312
  • 32 Voicu S, Delrue M, Chousterman BG. et al. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications. Eur Rev Med Pharmacol Sci 2020; 24 (17) 9161-9168
  • 33 Kiss S, Gede N, Hegyi P. et al. Early changes in laboratory parameters are predictors of mortality and ICU admission in patients with COVID-19: a systematic review and meta-analysis. Med Microbiol Immunol (Berl) 2021; 210 (01) 33-47
  • 34 Lipcsey M, Persson B, Eriksson O. et al. The outcome of critically ill COVID-19 patients is linked to thromboinflammation dominated by the kallikrein/kinin system. Front Immunol 2021; 12: 627579
  • 35 Umemura Y, Yamakawa K, Kiguchi T, Nishida T, Kawada M, Fujimi S. Hematological phenotype of COVID-19-induced coagulopathy: far from typical sepsis-induced coagulopathy. J Clin Med 2020; 9 (09) E2875
  • 36 Goshua G, Pine AB, Meizlish ML. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7 (08) e575-e582
  • 37 von Meijenfeldt FA, Havervall S, Adelmeijer J. et al. Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. Res Pract Thromb Haemost 2020; 5 (01) 132-141
  • 38 Alabyad D, Rangaraju S, Liu M. et al. Validation of an admission coagulation panel for risk stratification of COVID-19 patients. PLoS One 2021; 16 (03) e0248230
  • 39 Ranucci M, Sitzia C, Baryshnikova E. et al. COVID-19-associated coagulopathy: biomarkers of thrombin generation and fibrinolysis leading the outcome. J Clin Med 2020; 9 (11) E3487
  • 40 Blasi A, von Meijenfeldt FA, Adelmeijer J. et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J Thromb Haemost 2020; 18 (10) 2646-2653
  • 41 Chen L, Hu W, Guo X. et al. Association of coagulation dysfunction with cardiac injury among hospitalized patients with COVID-19. Sci Rep 2021; 11 (01) 4432
  • 42 Han H, Yang L, Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58 (07) 1116-1120
  • 43 WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20 (08) e192-e197
  • 44 Guan W-J, Ni Z-Y, Hu Y. et al; China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
  • 45 Barry M, Althabit N, Akkielah L. et al. Clinical characteristics and outcomes of hospitalized COVID-19 patients in a MERS-CoV referral hospital during the peak of the pandemic. Int J Infect Dis 2021; 106: 43-51
  • 46 Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323 (11) 1061-1069
  • 47 Al-Samkari H, Karp Leaf RS, Dzik WH. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020; 136 (04) 489-500
  • 48 van den Berg MJW, Waanders D, Kooistra EJ, Kox M, Pickkers P. The value of D-dimer to predict pulmonary embolism in critically ill COVID-19 patients. J Crit Care 2021; 64: 18-21
  • 49 Tuck AA, White HL, Abdalla BA. et al. To scan or not to scan - D-dimers and computed tomography pulmonary angiography in the era of COVID-19. Clin Med (Lond) 2021; 21 (02) e155-e160
  • 50 Valle C, Bonaffini PA, Dal Corso M. et al. Association between pulmonary embolism and COVID-19 severe pneumonia: experience from two centers in the core of the infection Italian peak. Eur J Radiol 2021; 137: 109613
  • 51 Mouhat B, Besutti M, Bouiller K. et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J 2020; 56 (04) 2001811
  • 52 Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L. et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res 2020; 192: 23-26
  • 53 Fournier M, Faille D, Dossier A. et al. Arterial thrombotic events in adult inpatients with COVID-19. Mayo Clin Proc 2021; 96 (02) 295-303
  • 54 Tsaplin S, Schastlivtsev I, Zhuravlev S, Barinov V, Lobastov K, Caprini JA. The original and modified Caprini score equally predicts venous thromboembolism in COVID-19 patients. J Vasc Surg Venous Lymphat Disord 2021; 9 (06) 1371-1381.e4
  • 55 Piazza G, Campia U, Hurwitz S. et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol 2020; 76 (18) 2060-2072
  • 56 Samuel A, Mechineni A, Aronow WS, Ismail M, Manickam R. A review of the characteristics and outcomes of 900 COVID-19 patients hospitalized at a tertiary care medical center in New Jersey, USA. Arch Med Sci Atheroscler Dis 2020; 5: e306-e312
  • 57 Torres-Machorro A, Anguiano-Álvarez VM, Grimaldo-Gómez FA. et al. Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity. Thromb Res 2020; 196: 268-271
  • 58 Boytsov SA, Pogosova NV, Paleev FN. et al. Clinical characteristics and factors associated with poor outcomes in hospitalized patients with novel coronavirus infection COVID-19. Kardiologiia 2021; 61 (02) 4-14
  • 59 Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets 2020; 31 (06) 740-745
  • 60 Chen W, Li Z, Yang B. et al. Delayed-phase thrombocytopenia in patients with coronavirus disease 2019 (COVID-19). Br J Haematol 2020; 190 (02) 179-184
  • 61 Zhu Y, Zhang J, Li Y, Liu F, Zhou Q, Peng Z. Association between thrombocytopenia and 180-day prognosis of COVID-19 patients in intensive care units: a two-center observational study. PLoS One 2021; 16 (03) e0248671
  • 62 Gabbai-Armelin PR, de Oliveira AB, Ferrisse TM. et al. COVID-19 (SARS-CoV-2) infection and thrombotic conditions: a systematic review and meta-analysis. Eur J Clin Invest 2021; 51 (06) e13559
  • 63 Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. Blood 2018; 132 (02) 141-147
  • 64 Doevelaar AAN, Bachmann M, Hölzer B. et al. von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019. Crit Care Med 2021; 49 (05) e512-e520
  • 65 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 2020; 383 (02) 120-128
  • 66 Philippe A, Chocron R, Gendron N. et al. Circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 2021; 24 (03) 505-517
  • 67 Sweeney JM, Barouqa M, Krause GJ, Gonzalez-Lugo JD, Rahman S, Gil MR. Low ADAMTS13 activity correlates with increased mortality in COVID-19 patients. TH Open 2021; 5 (01) e89-e103
  • 68 Ladikou EE, Sivaloganathan H, Milne KM. et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?. Clin Med (Lond) 2020; 20 (05) e178-e182
  • 69 Henry BM, Benoit SW, de Oliveira MHS, Lippi G, Favaloro EJ, Benoit JL. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy. Int J Lab Hematol 2021; 43 (Suppl. 01) 129-136
  • 70 Turecek PL, Peck RC, Rangarajan S. et al. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thromb Res 2021; 201: 100-112
  • 71 Taha M, Sano D, Hanoudi S. et al. Platelets and renal failure in the SARS-CoV-2 syndrome. Platelets 2021; 32 (01) 130-137
  • 72 Comer SP, Cullivan S, Szklanna PB. et al; COCOON Study Investigators. COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biol 2021; 19 (02) e3001109
  • 73 Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology 2021; 88 (01) 15-27
  • 74 Cohen A, Harari E, Cipok M. et al. Immature platelets in patients hospitalized with COVID-19. J Thromb Thrombolysis 2021; 51 (03) 608-616
  • 75 Zaid Y, Puhm F, Allaeys I. et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ Res 2020; 127 (11) 1404-1418
  • 76 Manne BK, Denorme F, Middleton EA. et al. Platelet gene expression and function in patients with COVID-19. Blood 2020; 136 (11) 1317-1329
  • 77 Pelzl L, Singh A, Funk J. et al. Antibody-mediated procoagulant platelet formation in COVID-19 is AKT dependent. J Thromb Haemost 2022; 20 (02) 387-398
  • 78 Althaus K, Marini I, Zlamal J. et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood 2021; 137 (08) 1061-1071
  • 79 Zlamal J, Althaus K, Jaffal H. et al. Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19. Blood Adv 2022; Jan 11; 6 (01) 248-258
  • 80 Nazy I, Jevtic SD, Moore JC. et al. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J Thromb Haemost 2021; 19 (05) 1342-1347
  • 81 Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285 (01) L20-L28
  • 82 Hardy M, Michaux I, Lessire S. et al. Prothrombotic disturbances of hemostasis of patients with severe COVID-19: a prospective longitudinal observational study. Thromb Res 2021; 197: 20-23
  • 83 Zuo Y, Warnock M, Harbaugh A. et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep 2021; 11 (01) 1580
  • 84 Spyropoulos AC, Levy JH, Ageno W. et al; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1859-1865
  • 85 Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. 2020 . Accessed February 15, 2022 at: https://b-s-h.org.uk/media/18171/th-and-covid-25-march-2020-final.pdf
  • 86 Nougier C, Benoit R, Simon M. et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost 2020; 18 (09) 2215-2219
  • 87 Kruse JM, Magomedov A, Kurreck A. et al. Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit Care 2020; 24 (01) 676
  • 88 Sadd C, Rowe T, Nazeef M, Kory P, Sultan S, Faust H. Thromboelastography to detect hypercoagulability and reduced fibrinolysis in coronavirus disease 2019 acute respiratory distress syndrome patients. Crit Care Explor 2020; 2 (09) e0192
  • 89 Mortus JR, Manek SE, Brubaker LS. et al. Thromboelastographic results and hypercoagulability syndrome in patients with coronavirus disease 2019 who are critically ill. JAMA Netw Open 2020; 3 (06) e2011192
  • 90 Panigada M, Bottino N, Tagliabue P. et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18 (07) 1738-1742
  • 91 Creel-Bulos C, Auld SC, Caridi-Scheible M. et al. Fibrinolysis shutdown and thrombosis in a COVID-19 ICU. Shock 2021; 55 (03) 316-320
  • 92 Hammer S, Häberle H, Schlensak C. et al. Severe SARS-CoV-2 infection inhibits fibrinolysis leading to changes in viscoelastic properties of blood clot: a descriptive study of fibrinolysis in COVID-19. Thromb Haemost 2021; 121 (11) 1417-1426
  • 93 Bachler M, Bösch J, Stürzel DP. et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth 2021; 126 (03) 590-598
  • 94 Bakchoul T, Hammer S, Lang P, Rosenberger P. Fibrinolysis shut down in COVID-19 patients: report on two severe cases with potential diagnostic and clinical relevance. Thrombosis Update 2020; 1: 100008
  • 95 Bouck EG, Denorme F, Holle LA. et al. COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity. Arterioscler Thromb Vasc Biol 2021; 41 (01) 401-414
  • 96 Thachil J, Cushman M, Srivastava A. A proposal for staging COVID-19 coagulopathy. Res Pract Thromb Haemost 2020; 4 (05) 731-736
  • 97 Gibson CM, Spyropoulos AC, Cohen AT. et al. The IMPROVEDD VTE Risk Score: incorporation of D-Dimer into the IMPROVE score to improve venous thromboembolism risk stratification. TH Open 2017; 1 (01) e56-e65
  • 98 Greco S, Zenunaj G, Bonsi B. et al. SARS-CoV-2 and finding of vein thrombosis: can IMPROVE and IMPROVEDD scores predict COVID-19 outcomes?. Eur Rev Med Pharmacol Sci 2021; 25 (04) 2123-2130
  • 99 Vlot EA, Van den Dool EJ, Hackeng CM, Sohne M, Noordzij PG, Van Dongen EPA. Anti Xa activity after high dose LMWH thrombosis prophylaxis in COVID 19 patients at the intensive care unit. Thromb Res 2020; 196: 1-3
  • 100 Thachil J, Tang N, Gando S. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18 (05) 1023-1026
  • 101 American Society of Hematology. COVID-19 and Coagulopathy. 2021 . Accessed March 8, 2021 at: https://www.hematology.org/covid-19/covid-19-and-coagulopathy
  • 102 American Society of Hematology. COVID-19 and VTE-Anticoagulation. 2021 . Accessed March 8, 2021 at: https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation
  • 103 Langer F, Kluge S, Klamroth R, Oldenburg J. Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis. Hamostaseologie 2020; 40 (03) 264-269
  • 104 National Institutes of Health (NIH). Antithrombotic Therapy in Patients with COVID-19. 2021 . Accessed March 8, 2021 at: https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/
  • 105 Barnes GD, Burnett A, Allen A. et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020; 50 (01) 72-81
  • 106 Moores LK, Tritschler T, Brosnahan S. et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report. Chest 2020; 158 (03) 1143-1163
  • 107 Horiuchi H, Morishita E, Urano T, Yokoyama K. Questionnaire-Survey Joint Team on the COVID-19-Related Thrombosis. COVID-19-related thrombosis in Japan: final report of a questionnaire-based survey in 2020. J Atheroscler Thromb 2021; 28 (04) 406-416
  • 108 Tassiopoulos AK, Mofakham S, Rubano JA. et al. D-dimer-driven anticoagulation reduces mortality in intubated COVID-19 patients: a cohort study with a propensity-matched analysis. Front Med (Lausanne) 2021; 8: 631335
  • 109 Stawiarski K, Loutoo A, Velardi L, Zarich S. D-dimer driven deep vein thrombosis prophylaxis strategy for hospitalized patients with COVID-19. Thromb Res 2021; 201: 151-153
  • 110 Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol 2020; 42 (Suppl. 01) 19-20
  • 111 Trunfio M, Salvador E, Cabodi D. et al; e-COVID Study Group. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. Thromb Res 2020; 196: 432-434
  • 112 Bergwerk M, Gonen T, Lustig Y. et al. COVID-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021; 385 (16) 1474-1484